Drug delivery is a rapidly growing area of research motivated by the nanotechnology
revolution, the ideal of personalized medicine, and the desire to reduce the side effects of …

Myeloid derived suppressor cells (MDSC) represent only a minor fraction of circulating blood
cells but play an important role in tumor formation and progression. They are a …

CIGB-247 is a novel cancer therapeutic vaccine that uses a human VEGF variant molecule
as antigen, in combination with a bacterial adjuvant. In mice, CIGB-247 has anti-tumor and …

CIGB-247 is a cancer therapeutic vaccine, based on recombinant modified human vascular
endothelial growth factor (VEGF) as antigen, in combination with the adjuvant VSSP, a …

Background Immune suppression is common in neoplasia and a major driver is tumor-
induced myeloid dysfunction. Yet, overcoming such myeloid cell defects remains an …

Improvement of patient survival by anti-angiogenic therapy has proven limited. A vaccination
approach inducing an immune response against the tumor vasculature combines the …

Despite the clinical success of the programmed death ligand 1 (PD-L1) blocking therapy in
cancer treatment, only a subset of patients exhibits durable responses, therefore further …

Background Colorectal cancer is one of the most common malignancies worldwide and is
associated with high mortality rates. We previously reported that Xanthium strumarium L …

Angiogenesis has a significant role in metastasis and progression of melanoma. Even small
tumors may be susceptible to metastasis and hence lead to a worse outcome in patients with …

Cancer vaccines have been developed as a new therapeutic approach, however, their
clinical benefit remains limited. We previously performed a phase II study for advanced …